The role of vitamin D supplementation in patients with rheumatic diseases

Nature Reviews Rheumatology

Volumn 9, Issue 7, 2013, Pages 411-422

  Abrahamsen, Bo ^a   Harvey, Nicholas C ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 24,25 DIHYDROXYVITAMIN D; 25 HYDROXYVITAMIN D; ALENDRONIC ACID; ALFACALCIDOL; C REACTIVE PROTEIN; CALCIFEDIOL; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CHOLESTEROL; CLODRONIC ACID; COLECALCIFEROL; COMPLEMENT COMPONENT C1Q ANTIBODY; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOUBLE STRANDED DNA ANTIBODY; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; GLUCOCORTICOID; INTERLEUKIN 2; PARATHYROID HORMONE; PLACEBO; VITAMIN D; VITAMIN D BINDING PROTEIN; ZOLEDRONIC ACID;

ADAPTIVE IMMUNITY; ALLELE; ANKYLOSING SPONDYLITIS; ANTIBODY DETECTION; BIOLOGICAL ACTIVITY; BONE MINERAL; BONE MINERALIZATION; CALCIUM ABSORPTION; CALCIUM METABOLISM; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; CELL ACTIVITY; CELL MIGRATION; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONNECTIVE TISSUE DISEASE; CORTICOSTEROID INDUCED OSTEOPOROSIS; CYTOKINE PRODUCTION; DIETARY INTAKE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; ENDOCRINE FUNCTION; FRAGILITY FRACTURE; GC GENE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HEART DISEASE; HEART INFARCTION; HORMONE BLOOD LEVEL; HUMAN; HYDROXYLATION; HYPERCALCEMIA; HYPOCALCEMIA; IMMUNITY; IN VITRO STUDY; INNATE IMMUNITY; JOINT CAVITY; LOW DRUG DOSE; MAMMAL; METABOLIC DISORDER; MONOTHERAPY; MUSCLE FUNCTION; MYOPATHY; MYOSITIS; NEPHROLITHIASIS; NONHUMAN; OSSIFICATION; OSTEOARTHRITIS; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT CARE; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; REGULATORY MECHANISM; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SARCOIDOSIS; SEASONAL VARIATION; SINGLE NUCLEOTIDE POLYMORPHISM; SKELETON; SKIN LUPUS ERYTHEMATOSUS; SPONDYLARTHRITIS; SUN EXPOSURE; SYSTEMIC LUPUS ERYTHEMATOSUS; THERAPY EFFECT; VDR GENE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION;

DIETARY SUPPLEMENTS; DISEASE MANAGEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RHEUMATIC DISEASES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84879887173     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2013.71     Document Type: Review

References (122)

1. Perwad, F. & Portale, A. A. Vitamin D metabolism in the kidney: regulation by phosphorus and fibroblast growth factor 23. Mol. Cell. Endocrinol. 347, 17-24 (2011).
2. St-Arnaud, R. Targeted inactivation of vitamin D hydroxylases in mice. Bone 25, 127-129 (1999). (Pubitemid 29322076)
3. 3. A metabolite of vitamin D effective on intestine. 3 J. Biol. Chem. 248, 6691-6696 (1973).
4. 3. J. Biol. Chem. 248, 4174-4180 (1973).
5. Ross, A. C., Taylor, C. L., Yaktine, A. L. & Del, H. B. IOM Dietary Reference Intakes for Calcium and Vitamin D. (The National Academies Press: Washington DC, 2011).
6. Adams, J. S. & Hewison, M. Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase. Arch. Biochem. Biophys. 523, 95-102 (2012).
7. 3 on type I IFN-mediated monocyte differentiation into dendritic cells: mpairment of functional activities and chemotaxis. J. Immunol. 174, 270-276 (2005). (Pubitemid 40007413)
8. 3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 173, 2909-2912 (2004).
9. Peelen, E. et al. Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun. Rev. 10, 733-743 (2011).
10. Harvey, N. C. & Cooper, C. Vitamin D: some perspective please. BMJ 345, e4695 (2012).
11. Mavroeidi, A. et al. Seasonal 25-hydroxyvitamin D changes in British postmenopausal women at 57 degrees N and 51 degrees N: a longitudinal study. J. Steroid Biochem. Mol. Biol. 121, 459-461 (2010).
12. Thuesen, B. et al. Determinants of vitamin D status in a general population of Danish adults. Bone 50, 605-610 (2012).
13. Arabi, A., El Rassi, R. & El-Hajj Fuleihan, G. Hypovitaminosis D in developing countries\prevalence, risk factors and outcomes. Nat Rev. Endocrinol. 6, 550-561 (2010).
14. Wallace, A. M., Gibson, S., De la Hunty, A., Lamberg-Allardt, C. & Ashwell, M. Measurement of 25-hydroxyvitamin D in the clinical laboratory: current procedures, performance characteristics and limitations. Steroids 75, 477-488 (2010).
15. Bolland, M. J., Grey, A. & Reid, I. R. Vitamin D and falls. Time for a moratorium on vitamin D meta-analyses? BMJ 339, b4394 (2009).
16. Tang, B. M., Eslick, G. D., Nowson, C., Smith, C. & Bensoussan, A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370, 657-666 (2007). (Pubitemid 47285316)
17. Abrahamsen, B. et al. Patient level pooled analysis of 68,500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 340, b5463 (2010).
18. Bischoff-Ferrari, H. A. et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N. Engl. J. Med. 367, 40-49 (2012).
19. Rosen, C. J. et al. IOM committee members respond to endocrine society vitamin D guideline. J. Clin. Endocrinol. Metab. 97, 1146-1152 (2012).
20. Holick, M. F. et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 1911-1930 (2011).
21. Heikinheimo, R. J. et al. Annual injection of vitamin D and fractures of aged bones. Calcif. Tissue Int. 51, 105-110 (1992).
22. Larsen, E. R., Mosekilde, L. & Foldspang, A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J. Bone Miner. Res. 19, 370-378 (2004). (Pubitemid 38787391)
23. Cummings, S. R. et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N. Engl. J. Med. 339, 733-738 (1998). (Pubitemid 28417356)
24. [No authors listed] Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis guidelines. Arthritis Rheum. 39, 1791-1801 (1996).
25. [No authors listed] ACR Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 44, 1496-1503 (2001).
26. Grossman, J. M. et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 62, 1515-1526 (2010).
27. Sambrook, P. et al. Prevention of corticosteroid osteoporosis. N. Engl. J. Med. 328, 1747-1752 (1993).
28. 3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 125, 961-968 (1996).
29. Adachi, J. D. et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J. Rheumatol. 23, 995-1000 (1996). (Pubitemid 26196087)
30. De Nijs, R. N. et al. Alendronate or alfacalcidol in glucocorticoid- induced osteoporosis. N. Engl. J. Med. 355, 675-684 (2006).
31. Silverman, S. Bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo and active controlled trial. J. Bone Miner. Res. 23, 1923-1934 (2008).
32. Black, D. M. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348, 1535-1541 (1996). (Pubitemid 26411651)
33. Mc Closkey, E. V. et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J. Bone Miner. Res. 22, 135-141 (2007). (Pubitemid 46032606)
34. Bourke, S. et al. The impact of dietary calcium intake and vitamin D status on the effects of zoledronate. Osteoporos. Int. 24, 349-354 (2012).
35. Srikuea, R., Zhang, X., Park-Sarge, O.-K. & Esser, K. A. VDR and CYP27B1 are expressed in C2C12 cells and regenerating skeletal muscle: potential role in suppression of myoblast proliferation. Am. J. Physiol. Cell Physiol. 303, C396-C405 (2012).
36. Wang, Y. & De Luca, H. F. Is the vitamin D receptor found in muscle? Endocrinology 152, 354-363 (2011).
37. Wang, Y., Zhu, J. & De Luca, H. F. Where is the vitamin D receptor? Arch. Biochem. Biophys. 523, 123-133 (2012).
38. Gerdhem, P., Ringsberg, K. A., Obrant, K. J. & Akesson, K. Association between 25-hydroxyvitamin D levels, physical activity muscle strength and fractures in the prospective population-based OPRA Study of Elderly Women. Osteoporos. Int. 16, 1425-1431 (2005). (Pubitemid 41534648)
39. Rosen, C. J. Vitamin D and falls\are intermittent, high doses better? Nat Rev. Endocrinol. 7, 695-696 (2011).
40. Glendenning, P. et al. Effects of three monthly oral 150,000 IU cholecalciferol supplementation on falls, mobility and muscle strength in older postmenopausal women: a randomised controlled trial. J. Bone Miner. Res. 27, 170-176 (2011).
41. Sanders, K. M. et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 303, 1815-1822 (2010).
42. Murad, M. H. et al. Clinical review: The effect of vitamin D on falls: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 96, 2997-3006 (2011).
43. Thudi, A., Yin, S., Wandstrat, A. E., Li, Q. Z. & Olsen, N. J. Vitamin D levels and disease status in Texas patients with systemic lupus erythematosus. Am. J. Med. Sci. 335, 99-104 (2008). (Pubitemid 351253404)
44. 3 in patients with systemic lupus erythematosus. Clin. Rheumatol. 14, 397-400 (1995).
45. Fragoso, T. S. et al. 25-Hydroxyivitamin D3 levels in patients with systemic lupus erythematosus and its association with clinical parameters and laboratory tests. Rev. Bras. Reumatol. 52, 60-65 (2012).
46. Hamza, R. T, Awwad, K. S., Ali, M. K. & Hamed, A. I. Reduced serum concentrations of 25-hydroxy vitamin D in Egyptian patients with systemic lupus erythematosus: relation to disease activity. Med. Sci. Monit 17, CR711-CR718 (2011).
47. Stockton, K. A., Kandiah, D. A., Paratz, J. D. & Bennell, K. L. Fatigue, muscle strength and vitamin D status in women with systemic lupus erythematosus compared with healthy controls. Lupus 21, 271-278 (2012).
48. Souto, M. et al. Vitamin D insufficiency in Brazilian patients with SLE: prevalence, associated factors, and relationship with activity Lupus 20, 1019-1026 (2011).
49. Lee, Y. H., Bae, S. C., Choi, S. J., Ji, J. D. & Song, G. G. Associations between vitamin D receptor polymorphisms and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Mol. Biol. Rep. 38, 3643-3651 (2011).
50. Mok, C. C. et al. Vitamin D deficiency as marker for disease activity and damage in systemic upus erythematosus: a comparison with anti-ds DNA and anti-C1q. Lupus 21, 36-42 (2012).
51. Szodoray, P. et al. The immunopathological role of vitamin D in patients with SLE: data from a single centre registry in Hungary. Scand. J. Rheumatol. 40, 122-126 (2011).
52. Birmingham, D. J. et al. Evidence that abnormally large seasonal declines in vitamin D status may trigger SLE flare in non-African Americans. Lupus 21, 855-864 (2012).
53. Reid, D. et al. The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty. Am. J. Clin. Nutr. 93, 1006-1011 (2011).
54. Gama, R. et al. Hypovitaminosis D and disease: consequence rather than cause? BMJ 345, e5706 (2012).
55. Heine, G., Lahl, A., Müller, C. & Worm, M. Vitamin D deficiency in patients with cutaneous upus erythematosus is prevalent throughout the year. Br. J. Dermatol. 163, 863-865 (2010).
56. Cutillas-Marco, E., Morales-Suárez-Varela, M., Marquina-Vila, A. & Grant, W. Serum 25-hydroxyvitamin D levels in patients with cutaneous lupus erythematosus in a Mediterranean region. Lupus 19, 810-814 (2010).
57. Cusack, C. et al. Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatol. Photoimmunol. Photomed. 24, 260-267 (2008).
58. Costenbader, K. H., Feskanich, D., Holmes, M., Karlson, E. W. & Benito-Garcia, E. Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann. Rheum. Dis. 67, 530-535 (2008). (Pubitemid 351498436)
59. Hacker-Thompson, A., Schloetter, M. & Sellmeyer, D. E. Validation of a dietary vitamin D questionnaire using multiple diet records and the block 98 health habits and history questionnaire in healthy postmenopausal women in northern California. J. Acad. Nutr. Diet 112, 419-423 (2012).
60. Ruiz-Irastorza, G., Gordo, S., Olivares, N., Egurbide, M. V. & Aguirre, C. Changes in vitamin D levels in patients with systemic lupus erythematosus: effects on fatigue, disease activity, and damage. Arthritis Care Res. 62, 1160-1165 (2010).
61. Aghdassi, E. et al. The use of micronutrient supplements is not associated with better quality of life and disease activity in Canadian patients with systemic lupus erythematosus. J. Rheumatol. 37, 87-90 (2010).
62. Azali, P. et al. Low serum levels of vitamin D in idiopathic inflammatory myopathies. Ann. Rheum. Dis. 72, 512-516 (2013).
63. Gambichler, T, Chrobok, I., Höxtermann, S. & Kreuter, A. Significantly decreased serum 25-hydroxyvitamin d levels in a large German systemic sclerosis cohort. J. Rheumatol. 38, 2492-2493 (2011).
64. Rios Fernández, R., Fernández Roldán, C., Callejas Rubio, J. L. & Ortego Centeno, N. Vitamin D deficiency in a cohort of patients with systemic scleroderma from the south of Spain. J. Rheumatol. 37, 1355; author reply 1356 (2010).
65. Vacca, A. et al. Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis. J. Rheumatol. 36, 1924-1929 (2009).
66. Caramaschi, P. et al. Very low levels of vitamin D in systemic sclerosis patients. Clin. Rheumatol. 29, 1419-1425 (2010).
67. Hulshof, M. M. et al. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J. Am. Acad. Dermatol. 43, 1017-1023 (2000).
68. Cutolo, M. Rheumatoid arthritis: circadian and circannual rhythms in RA. Nat Rev. Rheumatol. 7, 500-502 (2011).
69. Cutolo, M. et al. Circannual vitamin D serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin. Exp. Rheumatol. 24, 702-704 (2006). (Pubitemid 46138805)
70. Rossini, M. et al. Relationship of focal erosions, bone mineral density, and parathyroid hormone in rheumatoid arthritis. J. Rheumatol. 38, 997-1002 (2011).
71. Rossini, M. et al. Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability. Arthritis Res. Ther. 12, R216 (2010).
72. Kerr, G. S. et al. Prevalence of vitamin D insufficiency/deficiency in rheumatoid arthritis and associations with disease severity and activity. J. Rheumatol. 38, 53-59 (2011).
73. Haque, U. J. & Bartlett, S. J. Relationships among vitamin D, disease activity, pain and disability in rheumatoid arthritis. Clin. Exp. Rheumatol. 28, 745-747 (2010).
74. Turhanolu, A. D. et al. The relationship between vitamin D and disease activity and functional health status in rheumatoid arthritis. Rheumatol. Int. 31, 911-914 (2011).
75. Feser, M. et al. Plasma 25,OH vitamin D concentrations are not associated with rheumatoid arthritis (RA)-related autoantibodies in individuals at elevated risk for RA. J. Rheumatol. 36, 943-946 (2009).
76. Craig, S. M. et al. Vitamin D status and its associations with disease activity and severity in African Americans with recent-onset rheumatoid arthritis. J. Rheumatol. 37, 275-281 (2010).
77. Merlino, L. A. et al. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum. 50, 72-77 (2004). (Pubitemid 38084289)
78. 3 in rheumatoid arthritis patients. Clin. Exp. Rheumatol. 17, 453-456 (1999). (Pubitemid 29343630)
79. Uitterlinden, A. G. et al. Vitamin D receptor genotype is associated with radiographic osteoarthritis at the knee. J. Clin. Invest. 100, 259-263 (1997). (Pubitemid 27349071)
80. Huang, J., Ushiyama, T, Inoue, K., Kawasaki, T & Hukuda, S. Vitamin D receptor gene polymorphisms and osteoarthritis of the hand, hip, and knee: a case-control study in Japan. Rheumatology (Oxford) 39, 79-84 (2000). (Pubitemid 30095411)
81. Videman, T. et al. The relative roles of intragenic polymorphisms of the vitamin D receptor gene in umbar spine degeneration and bone density Spine (Phila. Pa. 1976) 26, E7-E12 (2001).
82. Solovieva, S. et al. Vitamin D receptor gene polymorphisms and susceptibility of hand osteoarthritis in Finnish women. Arthritis Res. Ther. 8, R20 (2006).
83. arc OGEN Constorium and arc OGEN Collaborators. Identification of new susceptibility loci for osteoarthritis (arc OGEN): a genome-wide association study. Lancet 380, 815-823 (2012).
84. Chaganti, R. K. et al. Association of 25-hydroxyvitamin D with prevalent osteoarthritis of the hip in elderly men: the osteoporotic fractures in men study. Arthritis Rheum. 62, 511-514 (2010).
85. Lane, N. E. et al. Serum vitamin D levels and incident changes of radiographic hip osteoarthritis: a longitudinal study. Study of Osteoporotic Fractures Research Group. Arthritis Rheum. 42, 854-860 (1999). (Pubitemid 29214995)
86. Ding, C. et al. Serum levels of vitamin D, sunlight exposure, and knee cartilage loss in older adults: the Tasmanian older adult cohort study. Arthritis Rheum. 60, 1381-1389 (2009).
87. Bergink, A. P. et al. Vitamin D status, bone mineral density, and the development of radiographic osteoarthritis of the knee: the Rotterdam Study. J. Clin. Rheumatol. 15, 230-237 (2009).
88. Felson, D. T. et al. Low levels of vitamin D and worsening of knee osteoarthritis: results of two longitudinal studies. Arthritis Rheum. 56, 129-136 (2007). (Pubitemid 46106185)
89. Muraki, S. et al. Association of vitamin D status with knee pain and radiographic knee osteoarthritis. Osteoarthritis Cartilage 19, 1301-1306 (2011).
90. Lange, U., Jung, O., Teichmann, J. & Neeck, G. Relationship between disease activity and serum levels of vitamin D metabolites and parathyroid hormone in ankylosing spondylitis. Osteoporos. Int. 12, 1031-1035 (2001). (Pubitemid 34105974)
91. Jung, K. H. et al. Associations of vitamin D binding protein gene polymorphisms with the development of peripheral arthritis and uveitis in ankylosing spondylitis. J. Rheumatol. 38, 2224-2229 (2011).
92. Fischer, R. et al. Discovery of candidate serum proteomic and metabolomic biomarkers in ankylosing spondylitis. Mol. Cell. Proteomics 11, M111.013904 (2012).
93. Touma, Z. et al. Seasonal variation in vitamin D levels in psoriatic arthritis patients from different latitudes and its association with clinical outcomes. Arthritis Care Res. 63, 1440-1447 (2011).
94. 3: a pilot study. Arthritis Rheum. 33, 1723-1727 (1990).
95. Heidari, B., Shirvani, J. S., Firouzjahi, A., Heidari, P. & Hajian-Tilaki, K. O. Association between nonspecific skeletal pain and vitamin D deficiency. Int. J. Rheum. Dis. 13, 340-346 (2010).
96. Bhatty, S. A. et al. Vitamin D deficiency in fibromyalgia. J. Pak. Med. Assoc. 60, 949-951 (2010).
97. Macfarlane, G. J. et al. An excess of widespread pain among South Asians: are low levels of vitamin D implicated? Ann. Rheum. Dis. 64, 1217-1219 (2005).
98. Mc Beth, J. et al. Musculoskeletal pain is associated with very low levels of vitamin D in men: results from the European Male Ageing Study. Ann. Rheum. Dis. 69, 1448-1452 (2010).
99. Straube, S., Derry, S., Moore, R. A. & Mc Quay, H. J. Vitamin D for the treatment of chronic painful conditions in adults. Cochrane Database of Systemic Reviews, Issue 1. Art. No.: CD007771 http://dx.doi.org/10.1002/ 14651858.CD007771.pub2.
100. Brohult, J. & Jonson, B. Effects of large doses of calciferol on patients with rheumatoid arthritis. A double-blind clinical trial. Scand. J. Rheumatol. 2, 173-176 (1973).
101. Di Munno, O. et al. Prevention of glucocorticoid-induced osteopenia: effect of oral 25-hydroxyvitamin D and calcium. Clin. Rheumatol. 8, 202-207 (1989). (Pubitemid 20122945)
102. Warner, A. E. & Arnspiger, S. A. Diffuse musculoskeletal pain is not associated with low vitamin D levels or improved by treatment with vitamin D. J. Clin. Rheumatol. 14, 12-16 (2008).
103. Yamauchi, Y. et al. A double blind trial of alfacalcidol on patients with rheumatoid arthritis (RA) [Japanese]. Ryumachi. 29, 11-24 (1989). (Pubitemid 19203991)
104. Richart, T., Li, Y. & Staessen, J. A. Renal versus extrarenal activation of vitamin D in relation to atherosclerosis, arterial stiffening, and hypertension. Am. J. Hypertens. 20, 1007-1015 (2007). (Pubitemid 47313623)
105. Michos, E. D. et al. 25-hydroxyvitamin D deficiency is associated with fatal stroke among whites but not blacks: The NHANES-III linked mortality files. Nutrition 28, 367-371 (2012).
106. Thomas, G. N. et al. Vitamin D levels predict all-cause and cardiovascular disease mortality in subjects with the metabolic syndrome: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Diabetes Care 35, 1158-1164 (2012).
107. Bolland, M. J. et al. Vitamin D insufficiency and health outcomes over 5 y in older women. Am. J. Clin. Nutr. 91, 82-89 (2010).
108. Wasson, L. T. et al. Is vitamin D deficiency a risk factor for ischemic heart disease in patients with established cardiovascular disease-10-year follow-up of the Nova Scotia Health Survey. Int. J. Cardiol. 148, 387-389 (2011).
109. Liu, L. C. Y. et al. Vitamin D status and outcomes in heart failure patients. Eur. J. Heart Fail. 13, 619-625 (2011).
110. Hsia, J. et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 115, 846-854 (2007). (Pubitemid 46294725)
111. Bolland, M. J. et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341, c3691 (2010).
112. Prince, R., Zhu, K. & Lewis, J. R. Evidence of harm is unconvincing. BMJ 342, d3541 (2011).
113. Abrahamsen, B. & Sahota, O. Do calcium plus vitamin D supplements increase cardiovascular risk? BMJ 342, d2080 (2011).
114. Aspray T. J. & Francis, R. M. Calcium and vitamin D supplementation and cardiovascular disease: quo vadis? Maturitas 69, 285-286 (2011).
115. Jackson, R. D. et al. Calcium plus vitamin D supplementation and the risk of fractures. N. Engl. J. Med. 354, 669-683 (2006). (Pubitemid 43247138)
116. Freedman, D. M., Looker, A. C., Abnet, C. C., Linet, M. S. & Graubard, B. I. Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III study (1988-2006). Cancer Res. 70, 8587-8597 (2010).
117. Chung, M., Lee, J., Terasawa, T, Lau, J. & Trikalinos, T. A. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann. Intern. Med. 155, 827-838 (2011).
118. Morimoto, T. et al. Epidemiology of sarcoidosis in Japan. Eur. Respir. J. 31, 372-379 (2008).
119. Sharma, O. P. Hypercalcemia in granulomatous disorders: a clinical review. Curr. Opin. Pulm. Med. 6, 442-447 (2000). (Pubitemid 30637660)
120. Burke, R. R., Rybicki, B. A. & Rao, D. S. Calcium and vitamin D in sarcoidosis: how to assess and manage. Semin. Respir. Crit Care Med. 31, 474-484 (2010).
121. Kavathia, D., Buckley, J. D., Rao, D., Rybicki, B. & Burke, R. Elevated 1,25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis. Respir. Med. 104, 564-570 (2010).
122. Bolland, M. J., Grey, A., Avenell, A., Gamble, G. D. & Reid, I. R. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 342, d2040 (2011).